Search clinical trials for: fluticasone propionate and salmeterol

Total 1294 results

GlaxoSmithKline

Completed

Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Australia, France, Romania, Finland, Taiwan, Bulgaria, Estonia, Canada, Netherlands, Philippines, South Africa, Sweden, Spain, Singapore, Austria, Germany, Latvia, New Zealand, China, Ukraine, Thailand, Greece, United Kingdom and more
GlaxoSmithKline

Completed

Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-

Bronchial Asthma

Japan
GlaxoSmithKline

Completed

Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Completed

A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma

Asthma

Germany, France
Teva Pharmaceuticals USA

Terminated

Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients

Seasonal Allergic Rhinitis

United States
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Bioequivalence

Greece
Pfizer

Completed

A Study To Determine Effects Of Fluticasone Propionate On Sputum Neutrophils After Inhaled Lipopolysaccharide Challenge In Volunteers

Pulmonary Disease, Chronic Obstructive

United Kingdom
Nemours Children's Clinic
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial (MICT)

Asthma

United States
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Intech Biopharm Ltd.

Completed

Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

Taiwan
University of Dundee

Completed

Fluticasone and Salmeterol in Allergic Rhinitis

Allergic Rhinitis

United Kingdom
NYU Langone Health
National Institute for Occupational Safety and Health (NIOSH/CDC)

Completed

Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program

Lung Diseases | Medication Compliance

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

Persistent Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

Asthma

United States
GlaxoSmithKline

Completed

Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy

Asthma
Almirall, S.A.

Completed

A Single-dose, Randomised, Crossover, Placebo-controlled Study Assessing Two Fixed-dose Combinations of Inhaled Long-acting Beta-agonist and Corticosteroid

Asthma

Germany, United Kingdom
Fudan University
The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaborators

Unknown

The Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Atropium/Albuterol in Patients COPD

Chronic Obstructive Pulmonary Disease (COPD)

China
GlaxoSmithKline

Completed

Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.

Pulmonary Disease, Chronic Obstructive

United States
University of Rostock
GlaxoSmithKline

Completed

Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers

Chronic Obstructive Pulmonary Disease | Smoke-related Lung Diseases

Germany
GlaxoSmithKline

Completed

Inhalation of Corticosteroids in Smoking and Non-smoking Asthmatics.

Asthma

United Kingdom, Belgium
Far Eastern Memorial Hospital
Research Ethics Review Committee

Unknown

Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients

Quality of Life | Percentage of Annual Acute Exacerbation

Taiwan
Taipei Veterans General Hospital, Taiwan
National Taiwan University Hospital; Far Eastern Memorial Hospital

Unknown

Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

Taiwan
GlaxoSmithKline

Completed

An Investigation of the Pharmacokinetics of GSK961081 and Fluticasone Propionate in Healthy Volunteers

Pulmonary Disease, Chronic Obstructive

United Kingdom
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade (BREATH-PK250-CC)

Bioequivalence

Greece
Padagis LLC

Completed

Randomized Study to Compare the Bioavailability of Two Fluticasone Propionate 0.005% Topical Ointments

Healthy
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Russian Federation, Spain, Netherlands, Hungary, Denmark, Poland, Czechia
GlaxoSmithKline

Completed

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Ukraine, Spain, South Africa, Italy
GlaxoSmithKline

Completed

Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)

Respiratory Disorders
Boehringer Ingelheim

Completed

BI 671800 ED in Steroid-naive Asthmatic Patients

Asthma

United States, Australia, Canada, Colombia, Korea, Republic of, Mexico, New Zealand, Peru, Philippines, Taiwan
Padagis LLC

Completed

Randomized Study to Compare the Bioequivalence of Two Fluticasone Propionate 0.05% Topical Creams

Healthy
GlaxoSmithKline

Completed

Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD).

Asthma

Australia
Boehringer Ingelheim

Completed

Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD

Pulmonary Disease, Chronic Obstructive

Austria, Canada, France, Germany, Italy, Russian Federation, Sweden
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Recruiting

Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma (AERO-PD)

Asthma

Greece
Respirent Pharmaceuticals Co Ltd.

Completed

A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma

Asthma

Greece
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus

Asthma

Finland
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus

Asthma

Finland
Bausch & Lomb Incorporated

Completed

Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis

United States
Novartis Pharmaceuticals

Completed

A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma

Asthma

China, Germany, United States, India, Korea, Republic of, Romania, South Africa, Croatia, Egypt, Russian Federation, Estonia, Hungary, Poland, Slovakia, Bulgaria, Czechia, Latvia, Guatemala, Serbia, Japan, Mexico, United Kingdom, Li... and more
GlaxoSmithKline

Completed

A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD). (ADC111114)

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

Pulmonary Disease, Chronic Obstructive

United States, Germany, Canada, Korea, Republic of
GlaxoSmithKline

Completed

Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

Pulmonary Disease, Chronic Obstructive

United States, Korea, Republic of, Chile, Poland, Czech Republic
Mundipharma Korea Ltd

Terminated

Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol (RECONFFIRM)

Asthma
GlaxoSmithKline

Completed

Special Drug Use Investigation for ADOAIR DISKUS COPD (Salmeterol and Fluticasone)

Pulmonary Disease, Chronic Obstructive

Japan
Novartis Pharmaceuticals

Terminated

Study of Safety of Foradil in Patients With Persistent Asthma

Persistent Asthma

United States
Novartis Pharmaceuticals

Withdrawn

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Chronic Obstructive Pulmonary Disease

Germany, Austria
GlaxoSmithKline

Completed

Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)

Respiratory Disorders
Boehringer Ingelheim

Completed

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Cardiovascular Function in COPD Patients

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients

Pulmonary Disease, Chronic Obstructive

Belgium, Czech Republic, Denmark, Germany, Hungary, Netherlands, Spain, Sweden

3

Subscribe